BRCA2 and ovarian cancer: Another possible explanation for not finding a risk-reducing effect of RRSO on breast cancer risk is that the optimal timing of RRSO to prevent tubal/ovarian cancer is between 35 and 40 years for BRCA1 GPV carriers and between 40 and 45 years for BRCA2 GPV.